# Episode 444: Treating MS with a GLP-1 with Dr. Ellen Mowry

Page: https://stenobird.com/podcast/realtalk-ms-779631/episode-444-treating-ms-with-a-glp-1-with-dr-ellen-mowry
Text version: https://stenobird.com/podcast/realtalk-ms-779631/episode-444-treating-ms-with-a-glp-1-with-dr-ellen-mowry.md
Podcast: [RealTalk MS](https://stenobird.com/podcast/realtalk-ms-779631)
Published: 2026-03-02T23:00:00+00:00
Episode link: https://realtalkms.com/444
Audio file: https://traffic.libsyn.com/secure/realtalkms/Episode_444_Treating_MS_with_a_GLP-1_with_Dr._Ellen_Mowry.mp3?dest-id=570470
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/realtalk-ms-779631/episodes/episode-444-treating-ms-with-a-glp-1-with-dr-ellen-mowry
Duration seconds: 1893

## Resource

You know them by their trade names such as Ozempic, Wegovy, Mounjaro, and Zepbound. This class of medications is known as GLP-1 receptor agonists. And while they are best known for managing diabetes and promoting weight loss, researchers are finding that these drugs are also effective in a broad range of other health conditions. So, what about MS? My guest this week is Dr. Ellen Mowry, the principal investigator of a clinical trial to determine whether a GLP-1 drug can reduce brain inflammation and provide neuroprotection in people living with progressive MS. We're sharing details about the discovery of a new biomarker that not only confirms an MS diagnosis but also predicts the severity of an individual's disease course in the years ahead. We'll tell you about three studies focused on better managing some of the most common MS symptoms and funded by the International Progressive MS Alliance. And we'll explain how Merck and the Mayo Clinic are partnering to build a first-of-its-kind drug discovery platform using AI. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A GLP-1 for MS? :22 I'm asking for your support: 1:31 Researchers discover biomarkers that can predict future disease course 2:13 The International Progressive MS Alliance invests $8.1 million in global studies that address the most common MS symptoms 5:44 Merck and the Mayo Clinic collaborate on AI-driven drug discovery platform 10:02 Dr. Ellen Mowry discusses the clinical trial to determine whether a GLP-1 drug can reduce inflammation in the central nervous system and offer neuroprotection to people with progressive MS 12:20 Share this episode 30:17 Next week 30:38 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/444 ADD…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/realtalk-ms-779631/episodes/episode-444-treating-ms-with-a-glp-1-with-dr-ellen-mowry/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/realtalk-ms-779631/episode-444-treating-ms-with-a-glp-1-with-dr-ellen-mowry.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.